Clinical Trial

A Study of PHN-012 in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Protocol Amendment History 3 changes
notable Trial sites expanded: 20 -> 26 locations 2026-08-07
notable Trial sites expanded: 13 -> 21 locations 2026-04-18
notable Trial sites expanded: 7 -> 13 locations 2026-04-01
Trial Details
NCT Number NCT07127874
Lead Sponsor Pheon Therapeutics
Conditions Colon Cancer, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Cancer, Advanced Solid Tumors
Enrollment 165 participants
Start Date 2025-09-23
Primary Completion 2027-09 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-06